FUTURA MEDICAL PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.45 GBX | +0.14% |
|
-0.56% | +39.02% |
| 10/04 | Futura Medical hails results as erectile dysfunction drug drives sales | AN |
| 10/04 | Transcript : Futura Medical plc, 2023 Earnings Call, Apr 10, 2024 |
| Sales 2023 | 3.1M 3.87M 323M | Sales 2024 * | 9.52M 11.89M 991M | Capitalization | 107M 133M 11.13B |
|---|---|---|---|---|---|
| Net income 2023 * | - | Net income 2024 * | -3 -3.75 -312.45 | EV / Sales 2023 | 22.3 x |
| Net cash position 2023 | 7.71M 9.64M 803M | Net cash position 2024 * | 2.94M 3.68M 306M | EV / Sales 2024 * | 10.9 x |
| P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-34.8
x | Employees | 12 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 67.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on Futura Medical plc
More press releases
| 1 day | +0.14% | ||
| 1 week | -0.56% | ||
| Current month | -12.47% | ||
| 1 month | -6.71% | ||
| 3 months | +17.00% | ||
| 6 months | +9.41% | ||
| Current year | +39.02% |
1 week
35.00
36.50
1 month
33.2143.80
Current year
25.5047.80
1 year
23.2867.00
3 years
23.2867.00
5 years
7.1684.00
10 years
5.6595.60
| Managers | Title | Age | Since |
|---|---|---|---|
James Barder
CEO | Chief Executive Officer | - | 01/01/01 |
Angela Hildreth
DFI | Director of Finance/CFO | - | 20/18/20 |
Ken James
CTO | Chief Tech/Sci/R&D Officer | - | 31/16/31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jeffrey Needham
CHM | Chairman | 68 | 08/21/08 |
Gordon Davis
BRD | Director/Board Member | 67 | 09/01 |
James Barder
CEO | Chief Executive Officer | - | 01/01/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 35.45 | +0.14% | 246,675 |
| 25/24/25 | 35.4 | -1.12% | 241,540 |
| 24/24/24 | 35.8 | +0.70% | 253,853 |
| 23/24/23 | 35.55 | -0.14% | 350,597 |
| 22/24/22 | 35.6 | -0.14% | 204,772 |
Delayed Quote London S.E., April 26, 2024 at 09:05 pm IST
More quotes
Futura Medical plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development and sale of pharmaceutical and healthcare products. It is focused on developing a portfolio of products based on its transdermal DermaSys technology. The DermaSys is designed to deliver clinically proven medical treatments via the skin. DermaSys platform with penetration and permeation enhancer components tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action. Such targeted delivery offers an optimized profile in terms of dose, onset time and duration of effect. The Company's products include MED3000 and TPR100. The Company's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The Company has conducted a Phase III study using MED3000 in ED. The Company is also developing CBD100, which is a topical cannabidiol formulation.
Calendar
11/09/2024
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.3545
GBP
Average target price
1.263
GBP
Spread / Average Target
+256.37%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +39.02% | 133M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- FUM Stock
